Human Vaccines-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data
Report Summary
Human Vaccines-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data offers a comprehensive analysis on Human Vaccines industry, standing on the readers’ perspective, delivering detailed market data in Global major 20 countries and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Top 20 Countries Market Size of Human Vaccines 2013-2017, and development forecast 2018-2023
Main manufacturers/suppliers of Human Vaccines worldwide and market share by regions, with company and product introduction, position in the Human Vaccines market
Market status and development trend of Human Vaccines by types and applications
Cost and profit status of Human Vaccines, and marketing status
Market growth drivers and challenges
The report segments the global Human Vaccines market as:
Global Human Vaccines Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
North America (United States, Canada and Mexico)
Europe (Germany, UK, France, Italy, Russia, Spain and Benelux)
Asia Pacific (China, Japan, India, Southeast Asia and Australia)
Latin America (Brazil, Argentina and Colombia)
Middle East and Africa
Global Human Vaccines Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Pneumococcal
Influenza
Hepatitis
HPV
Meningococcal
Rotavirus
Measles
Typhoid
Combination
Global Human Vaccines Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Pediatrics
Adolescents
Adults
Geriatrics
Global Human Vaccines Market: Manufacturers Segment Analysis (Company and Product introduction, Human Vaccines Sales Volume, Revenue, Price and Gross Margin):
AstraZeneca
Bavarian Nordic
Bharat Biotech
CSL Limited
Emergent BioSolutions, Inc.
GlaxoSmithKline plc
Johnson & Johnson
Merck & Co., Inc.
Mymetics
Novartis AG
Pfizer, Inc.
Sanofi
Shenzhen Kangtai Biological Products Co., Ltd.
Takeda Pharmaceutical Company Limited.
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Human Vaccines-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data offers a comprehensive analysis on Human Vaccines industry, standing on the readers’ perspective, delivering detailed market data in Global major 20 countries and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Top 20 Countries Market Size of Human Vaccines 2013-2017, and development forecast 2018-2023
Main manufacturers/suppliers of Human Vaccines worldwide and market share by regions, with company and product introduction, position in the Human Vaccines market
Market status and development trend of Human Vaccines by types and applications
Cost and profit status of Human Vaccines, and marketing status
Market growth drivers and challenges
The report segments the global Human Vaccines market as:
Global Human Vaccines Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
North America (United States, Canada and Mexico)
Europe (Germany, UK, France, Italy, Russia, Spain and Benelux)
Asia Pacific (China, Japan, India, Southeast Asia and Australia)
Latin America (Brazil, Argentina and Colombia)
Middle East and Africa
Global Human Vaccines Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Pneumococcal
Influenza
Hepatitis
HPV
Meningococcal
Rotavirus
Measles
Typhoid
Combination
Global Human Vaccines Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Pediatrics
Adolescents
Adults
Geriatrics
Global Human Vaccines Market: Manufacturers Segment Analysis (Company and Product introduction, Human Vaccines Sales Volume, Revenue, Price and Gross Margin):
AstraZeneca
Bavarian Nordic
Bharat Biotech
CSL Limited
Emergent BioSolutions, Inc.
GlaxoSmithKline plc
Johnson & Johnson
Merck & Co., Inc.
Mymetics
Novartis AG
Pfizer, Inc.
Sanofi
Shenzhen Kangtai Biological Products Co., Ltd.
Takeda Pharmaceutical Company Limited.
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF HUMAN VACCINES
1.1 Definition of Human Vaccines in This Report
1.2 Commercial Types of Human Vaccines
1.2.1 Pneumococcal
1.2.2 Influenza
1.2.3 Hepatitis
1.2.4 HPV
1.2.5 Meningococcal
1.2.6 Rotavirus
1.2.7 Measles
1.2.8 Typhoid
1.2.9 Combination
1.3 Downstream Application of Human Vaccines
1.3.1 Pediatrics
1.3.2 Adolescents
1.3.3 Adults
1.3.4 Geriatrics
1.4 Development History of Human Vaccines
1.5 Market Status and Trend of Human Vaccines 2013-2023
1.5.1 Global Human Vaccines Market Status and Trend 2013-2023
1.5.2 Regional Human Vaccines Market Status and Trend 2013-2023
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Human Vaccines 2013-2017
2.2 Sales Market of Human Vaccines by Regions
2.2.1 Sales Volume of Human Vaccines by Regions
2.2.2 Sales Value of Human Vaccines by Regions
2.3 Production Market of Human Vaccines by Regions
2.4 Global Market Forecast of Human Vaccines 2018-2023
2.4.1 Global Market Forecast of Human Vaccines 2018-2023
2.4.2 Market Forecast of Human Vaccines by Regions 2018-2023
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Sales Volume of Human Vaccines by Types
3.2 Sales Value of Human Vaccines by Types
3.3 Market Forecast of Human Vaccines by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Global Sales Volume of Human Vaccines by Downstream Industry
4.2 Global Market Forecast of Human Vaccines by Downstream Industry
CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
5.1 North America Human Vaccines Market Status by Countries
5.1.1 North America Human Vaccines Sales by Countries (2013-2017)
5.1.2 North America Human Vaccines Revenue by Countries (2013-2017)
5.1.3 United States Human Vaccines Market Status (2013-2017)
5.1.4 Canada Human Vaccines Market Status (2013-2017)
5.1.5 Mexico Human Vaccines Market Status (2013-2017)
5.2 North America Human Vaccines Market Status by Manufacturers
5.3 North America Human Vaccines Market Status by Type (2013-2017)
5.3.1 North America Human Vaccines Sales by Type (2013-2017)
5.3.2 North America Human Vaccines Revenue by Type (2013-2017)
5.4 North America Human Vaccines Market Status by Downstream Industry (2013-2017)
CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
6.1 Europe Human Vaccines Market Status by Countries
6.1.1 Europe Human Vaccines Sales by Countries (2013-2017)
6.1.2 Europe Human Vaccines Revenue by Countries (2013-2017)
6.1.3 Germany Human Vaccines Market Status (2013-2017)
6.1.4 UK Human Vaccines Market Status (2013-2017)
6.1.5 France Human Vaccines Market Status (2013-2017)
6.1.6 Italy Human Vaccines Market Status (2013-2017)
6.1.7 Russia Human Vaccines Market Status (2013-2017)
6.1.8 Spain Human Vaccines Market Status (2013-2017)
6.1.9 Benelux Human Vaccines Market Status (2013-2017)
6.2 Europe Human Vaccines Market Status by Manufacturers
6.3 Europe Human Vaccines Market Status by Type (2013-2017)
6.3.1 Europe Human Vaccines Sales by Type (2013-2017)
6.3.2 Europe Human Vaccines Revenue by Type (2013-2017)
6.4 Europe Human Vaccines Market Status by Downstream Industry (2013-2017)
CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
7.1 Asia Pacific Human Vaccines Market Status by Countries
7.1.1 Asia Pacific Human Vaccines Sales by Countries (2013-2017)
7.1.2 Asia Pacific Human Vaccines Revenue by Countries (2013-2017)
7.1.3 China Human Vaccines Market Status (2013-2017)
7.1.4 Japan Human Vaccines Market Status (2013-2017)
7.1.5 India Human Vaccines Market Status (2013-2017)
7.1.6 Southeast Asia Human Vaccines Market Status (2013-2017)
7.1.7 Australia Human Vaccines Market Status (2013-2017)
7.2 Asia Pacific Human Vaccines Market Status by Manufacturers
7.3 Asia Pacific Human Vaccines Market Status by Type (2013-2017)
7.3.1 Asia Pacific Human Vaccines Sales by Type (2013-2017)
7.3.2 Asia Pacific Human Vaccines Revenue by Type (2013-2017)
7.4 Asia Pacific Human Vaccines Market Status by Downstream Industry (2013-2017)
CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
8.1 Latin America Human Vaccines Market Status by Countries
8.1.1 Latin America Human Vaccines Sales by Countries (2013-2017)
8.1.2 Latin America Human Vaccines Revenue by Countries (2013-2017)
8.1.3 Brazil Human Vaccines Market Status (2013-2017)
8.1.4 Argentina Human Vaccines Market Status (2013-2017)
8.1.5 Colombia Human Vaccines Market Status (2013-2017)
8.2 Latin America Human Vaccines Market Status by Manufacturers
8.3 Latin America Human Vaccines Market Status by Type (2013-2017)
8.3.1 Latin America Human Vaccines Sales by Type (2013-2017)
8.3.2 Latin America Human Vaccines Revenue by Type (2013-2017)
8.4 Latin America Human Vaccines Market Status by Downstream Industry (2013-2017)
CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
9.1 Middle East and Africa Human Vaccines Market Status by Countries
9.1.1 Middle East and Africa Human Vaccines Sales by Countries (2013-2017)
9.1.2 Middle East and Africa Human Vaccines Revenue by Countries (2013-2017)
9.1.3 Middle East Human Vaccines Market Status (2013-2017)
9.1.4 Africa Human Vaccines Market Status (2013-2017)
9.2 Middle East and Africa Human Vaccines Market Status by Manufacturers
9.3 Middle East and Africa Human Vaccines Market Status by Type (2013-2017)
9.3.1 Middle East and Africa Human Vaccines Sales by Type (2013-2017)
9.3.2 Middle East and Africa Human Vaccines Revenue by Type (2013-2017)
9.4 Middle East and Africa Human Vaccines Market Status by Downstream Industry (2013-2017)
CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF HUMAN VACCINES
10.1 Global Economy Situation and Trend Overview
10.2 Human Vaccines Downstream Industry Situation and Trend Overview
CHAPTER 11 HUMAN VACCINES MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
11.1 Production Volume of Human Vaccines by Major Manufacturers
11.2 Production Value of Human Vaccines by Major Manufacturers
11.3 Basic Information of Human Vaccines by Major Manufacturers
11.3.1 Headquarters Location and Established Time of Human Vaccines Major Manufacturer
11.3.2 Employees and Revenue Level of Human Vaccines Major Manufacturer
11.4 Market Competition News and Trend
11.4.1 Merger, Consolidation or Acquisition News
11.4.2 Investment or Disinvestment News
11.4.3 New Product Development and Launch
CHAPTER 12 HUMAN VACCINES MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
12.1 AstraZeneca
12.1.1 Company profile
12.1.2 Representative Human Vaccines Product
12.1.3 Human Vaccines Sales, Revenue, Price and Gross Margin of AstraZeneca
12.2 Bavarian Nordic
12.2.1 Company profile
12.2.2 Representative Human Vaccines Product
12.2.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Bavarian Nordic
12.3 Bharat Biotech
12.3.1 Company profile
12.3.2 Representative Human Vaccines Product
12.3.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Bharat Biotech
12.4 CSL Limited
12.4.1 Company profile
12.4.2 Representative Human Vaccines Product
12.4.3 Human Vaccines Sales, Revenue, Price and Gross Margin of CSL Limited
12.5 Emergent BioSolutions, Inc.
12.5.1 Company profile
12.5.2 Representative Human Vaccines Product
12.5.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Emergent BioSolutions, Inc.
12.6 GlaxoSmithKline plc
12.6.1 Company profile
12.6.2 Representative Human Vaccines Product
12.6.3 Human Vaccines Sales, Revenue, Price and Gross Margin of GlaxoSmithKline plc
12.7 Johnson & Johnson
12.7.1 Company profile
12.7.2 Representative Human Vaccines Product
12.7.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Johnson & Johnson
12.8 Merck & Co., Inc.
12.8.1 Company profile
12.8.2 Representative Human Vaccines Product
12.8.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Merck & Co., Inc.
12.9 Mymetics
12.9.1 Company profile
12.9.2 Representative Human Vaccines Product
12.9.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Mymetics
12.10 Novartis AG
12.10.1 Company profile
12.10.2 Representative Human Vaccines Product
12.10.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Novartis AG
12.11 Pfizer, Inc.
12.11.1 Company profile
12.11.2 Representative Human Vaccines Product
12.11.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Pfizer, Inc.
12.12 Sanofi
12.12.1 Company profile
12.12.2 Representative Human Vaccines Product
12.12.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Sanofi
12.13 Shenzhen Kangtai Biological Products Co., Ltd.
12.13.1 Company profile
12.13.2 Representative Human Vaccines Product
12.13.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Shenzhen Kangtai Biological Products Co., Ltd.
12.14 Takeda Pharmaceutical Company Limited.
12.14.1 Company profile
12.14.2 Representative Human Vaccines Product
12.14.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Takeda Pharmaceutical Company Limited.
CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF HUMAN VACCINES
13.1 Industry Chain of Human Vaccines
13.2 Upstream Market and Representative Companies Analysis
13.3 Downstream Market and Representative Companies Analysis
CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF HUMAN VACCINES
14.1 Cost Structure Analysis of Human Vaccines
14.2 Raw Materials Cost Analysis of Human Vaccines
14.3 Labor Cost Analysis of Human Vaccines
14.4 Manufacturing Expenses Analysis of Human Vaccines
CHAPTER 15 REPORT CONCLUSION
CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE
16.1 Methodology/Research Approach
16.1.1 Research Programs/Design
16.1.2 Market Size Estimation
16.1.3 Market Breakdown and Data Triangulation
16.2 Data Source
16.2.1 Secondary Sources
16.2.2 Primary Sources
16.3 Reference
1.1 Definition of Human Vaccines in This Report
1.2 Commercial Types of Human Vaccines
1.2.1 Pneumococcal
1.2.2 Influenza
1.2.3 Hepatitis
1.2.4 HPV
1.2.5 Meningococcal
1.2.6 Rotavirus
1.2.7 Measles
1.2.8 Typhoid
1.2.9 Combination
1.3 Downstream Application of Human Vaccines
1.3.1 Pediatrics
1.3.2 Adolescents
1.3.3 Adults
1.3.4 Geriatrics
1.4 Development History of Human Vaccines
1.5 Market Status and Trend of Human Vaccines 2013-2023
1.5.1 Global Human Vaccines Market Status and Trend 2013-2023
1.5.2 Regional Human Vaccines Market Status and Trend 2013-2023
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Human Vaccines 2013-2017
2.2 Sales Market of Human Vaccines by Regions
2.2.1 Sales Volume of Human Vaccines by Regions
2.2.2 Sales Value of Human Vaccines by Regions
2.3 Production Market of Human Vaccines by Regions
2.4 Global Market Forecast of Human Vaccines 2018-2023
2.4.1 Global Market Forecast of Human Vaccines 2018-2023
2.4.2 Market Forecast of Human Vaccines by Regions 2018-2023
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Sales Volume of Human Vaccines by Types
3.2 Sales Value of Human Vaccines by Types
3.3 Market Forecast of Human Vaccines by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Global Sales Volume of Human Vaccines by Downstream Industry
4.2 Global Market Forecast of Human Vaccines by Downstream Industry
CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
5.1 North America Human Vaccines Market Status by Countries
5.1.1 North America Human Vaccines Sales by Countries (2013-2017)
5.1.2 North America Human Vaccines Revenue by Countries (2013-2017)
5.1.3 United States Human Vaccines Market Status (2013-2017)
5.1.4 Canada Human Vaccines Market Status (2013-2017)
5.1.5 Mexico Human Vaccines Market Status (2013-2017)
5.2 North America Human Vaccines Market Status by Manufacturers
5.3 North America Human Vaccines Market Status by Type (2013-2017)
5.3.1 North America Human Vaccines Sales by Type (2013-2017)
5.3.2 North America Human Vaccines Revenue by Type (2013-2017)
5.4 North America Human Vaccines Market Status by Downstream Industry (2013-2017)
CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
6.1 Europe Human Vaccines Market Status by Countries
6.1.1 Europe Human Vaccines Sales by Countries (2013-2017)
6.1.2 Europe Human Vaccines Revenue by Countries (2013-2017)
6.1.3 Germany Human Vaccines Market Status (2013-2017)
6.1.4 UK Human Vaccines Market Status (2013-2017)
6.1.5 France Human Vaccines Market Status (2013-2017)
6.1.6 Italy Human Vaccines Market Status (2013-2017)
6.1.7 Russia Human Vaccines Market Status (2013-2017)
6.1.8 Spain Human Vaccines Market Status (2013-2017)
6.1.9 Benelux Human Vaccines Market Status (2013-2017)
6.2 Europe Human Vaccines Market Status by Manufacturers
6.3 Europe Human Vaccines Market Status by Type (2013-2017)
6.3.1 Europe Human Vaccines Sales by Type (2013-2017)
6.3.2 Europe Human Vaccines Revenue by Type (2013-2017)
6.4 Europe Human Vaccines Market Status by Downstream Industry (2013-2017)
CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
7.1 Asia Pacific Human Vaccines Market Status by Countries
7.1.1 Asia Pacific Human Vaccines Sales by Countries (2013-2017)
7.1.2 Asia Pacific Human Vaccines Revenue by Countries (2013-2017)
7.1.3 China Human Vaccines Market Status (2013-2017)
7.1.4 Japan Human Vaccines Market Status (2013-2017)
7.1.5 India Human Vaccines Market Status (2013-2017)
7.1.6 Southeast Asia Human Vaccines Market Status (2013-2017)
7.1.7 Australia Human Vaccines Market Status (2013-2017)
7.2 Asia Pacific Human Vaccines Market Status by Manufacturers
7.3 Asia Pacific Human Vaccines Market Status by Type (2013-2017)
7.3.1 Asia Pacific Human Vaccines Sales by Type (2013-2017)
7.3.2 Asia Pacific Human Vaccines Revenue by Type (2013-2017)
7.4 Asia Pacific Human Vaccines Market Status by Downstream Industry (2013-2017)
CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
8.1 Latin America Human Vaccines Market Status by Countries
8.1.1 Latin America Human Vaccines Sales by Countries (2013-2017)
8.1.2 Latin America Human Vaccines Revenue by Countries (2013-2017)
8.1.3 Brazil Human Vaccines Market Status (2013-2017)
8.1.4 Argentina Human Vaccines Market Status (2013-2017)
8.1.5 Colombia Human Vaccines Market Status (2013-2017)
8.2 Latin America Human Vaccines Market Status by Manufacturers
8.3 Latin America Human Vaccines Market Status by Type (2013-2017)
8.3.1 Latin America Human Vaccines Sales by Type (2013-2017)
8.3.2 Latin America Human Vaccines Revenue by Type (2013-2017)
8.4 Latin America Human Vaccines Market Status by Downstream Industry (2013-2017)
CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
9.1 Middle East and Africa Human Vaccines Market Status by Countries
9.1.1 Middle East and Africa Human Vaccines Sales by Countries (2013-2017)
9.1.2 Middle East and Africa Human Vaccines Revenue by Countries (2013-2017)
9.1.3 Middle East Human Vaccines Market Status (2013-2017)
9.1.4 Africa Human Vaccines Market Status (2013-2017)
9.2 Middle East and Africa Human Vaccines Market Status by Manufacturers
9.3 Middle East and Africa Human Vaccines Market Status by Type (2013-2017)
9.3.1 Middle East and Africa Human Vaccines Sales by Type (2013-2017)
9.3.2 Middle East and Africa Human Vaccines Revenue by Type (2013-2017)
9.4 Middle East and Africa Human Vaccines Market Status by Downstream Industry (2013-2017)
CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF HUMAN VACCINES
10.1 Global Economy Situation and Trend Overview
10.2 Human Vaccines Downstream Industry Situation and Trend Overview
CHAPTER 11 HUMAN VACCINES MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
11.1 Production Volume of Human Vaccines by Major Manufacturers
11.2 Production Value of Human Vaccines by Major Manufacturers
11.3 Basic Information of Human Vaccines by Major Manufacturers
11.3.1 Headquarters Location and Established Time of Human Vaccines Major Manufacturer
11.3.2 Employees and Revenue Level of Human Vaccines Major Manufacturer
11.4 Market Competition News and Trend
11.4.1 Merger, Consolidation or Acquisition News
11.4.2 Investment or Disinvestment News
11.4.3 New Product Development and Launch
CHAPTER 12 HUMAN VACCINES MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
12.1 AstraZeneca
12.1.1 Company profile
12.1.2 Representative Human Vaccines Product
12.1.3 Human Vaccines Sales, Revenue, Price and Gross Margin of AstraZeneca
12.2 Bavarian Nordic
12.2.1 Company profile
12.2.2 Representative Human Vaccines Product
12.2.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Bavarian Nordic
12.3 Bharat Biotech
12.3.1 Company profile
12.3.2 Representative Human Vaccines Product
12.3.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Bharat Biotech
12.4 CSL Limited
12.4.1 Company profile
12.4.2 Representative Human Vaccines Product
12.4.3 Human Vaccines Sales, Revenue, Price and Gross Margin of CSL Limited
12.5 Emergent BioSolutions, Inc.
12.5.1 Company profile
12.5.2 Representative Human Vaccines Product
12.5.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Emergent BioSolutions, Inc.
12.6 GlaxoSmithKline plc
12.6.1 Company profile
12.6.2 Representative Human Vaccines Product
12.6.3 Human Vaccines Sales, Revenue, Price and Gross Margin of GlaxoSmithKline plc
12.7 Johnson & Johnson
12.7.1 Company profile
12.7.2 Representative Human Vaccines Product
12.7.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Johnson & Johnson
12.8 Merck & Co., Inc.
12.8.1 Company profile
12.8.2 Representative Human Vaccines Product
12.8.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Merck & Co., Inc.
12.9 Mymetics
12.9.1 Company profile
12.9.2 Representative Human Vaccines Product
12.9.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Mymetics
12.10 Novartis AG
12.10.1 Company profile
12.10.2 Representative Human Vaccines Product
12.10.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Novartis AG
12.11 Pfizer, Inc.
12.11.1 Company profile
12.11.2 Representative Human Vaccines Product
12.11.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Pfizer, Inc.
12.12 Sanofi
12.12.1 Company profile
12.12.2 Representative Human Vaccines Product
12.12.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Sanofi
12.13 Shenzhen Kangtai Biological Products Co., Ltd.
12.13.1 Company profile
12.13.2 Representative Human Vaccines Product
12.13.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Shenzhen Kangtai Biological Products Co., Ltd.
12.14 Takeda Pharmaceutical Company Limited.
12.14.1 Company profile
12.14.2 Representative Human Vaccines Product
12.14.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Takeda Pharmaceutical Company Limited.
CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF HUMAN VACCINES
13.1 Industry Chain of Human Vaccines
13.2 Upstream Market and Representative Companies Analysis
13.3 Downstream Market and Representative Companies Analysis
CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF HUMAN VACCINES
14.1 Cost Structure Analysis of Human Vaccines
14.2 Raw Materials Cost Analysis of Human Vaccines
14.3 Labor Cost Analysis of Human Vaccines
14.4 Manufacturing Expenses Analysis of Human Vaccines
CHAPTER 15 REPORT CONCLUSION
CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE
16.1 Methodology/Research Approach
16.1.1 Research Programs/Design
16.1.2 Market Size Estimation
16.1.3 Market Breakdown and Data Triangulation
16.2 Data Source
16.2.1 Secondary Sources
16.2.2 Primary Sources
16.3 Reference
